China's 3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin After U.S. Delays
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Canada's Isotechnika Pharma has signed a new deal with Chinese drug maker 3SBio on the development and commercialization of Isotechnika's voclosporin, which helps suppress the immune system's rejection of transplanted organs
You may also be interested in...
From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.
From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.
Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt
"Several outstanding issues" forced FDA to cancel the meeting, the agency said.